Abstract
Despite the versatility of enzyme-mediated oligosaccharide assembly, it has as a limitation that not all glycosyl transferases or glycan-modifying enzymes are readily available to install all natural occurring terminal epitopes. Here a chemoenzymatic strategy is described in which a core oligosaccharide is assembled enzymatically that is subjected to chemical manipulations to install complex terminal epitopes. It provided an unprecedented panel of human natural killer-1 (HSO3–3GlcAβ1–3Galβ1–4GlcNAc)-containing oligosaccharides and derivatives thereof. The compounds were printed as a microarray to examine binding specificities of serum antibodies of patients suffering from anti-myelin-associated glycoprotein neuropathy. All samples required glucuronic acid for antibody binding; however, variable dependence was observed for the length of the LacNAc chain and sulfation of glucuronic acid. Most serum samples required a lacto-neohexaose backbone indicating glycosphingolipids are being targeted. The clinical spectrum of immunoglobulin M monoclonal gammopathy varies, and the glycan microarray provides a more reliable platform for disease diagnosis and prognosis. [Figure not available: see fulltext.]
| Original language | English |
|---|---|
| Pages (from-to) | 85-98 |
| Number of pages | 14 |
| Journal | Nature Synthesis |
| Volume | 3 |
| Issue number | 1 |
| Early online date | 2 Oct 2023 |
| DOIs | |
| Publication status | Published - Jan 2024 |
Bibliographical note
Funding Information:This research was supported by TOP-PUNT grant 718.015.003 of the Netherlands Organization for Scientific Research (to G.-J.B.) and ERC-ADG grant 101020769 of the European Commission (to G.-J.B.). R.H. was funded by the GBS/CIDP Foundation International and the T2B collaboration project funded by PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
Funding
This research was supported by TOP-PUNT grant 718.015.003 of the Netherlands Organization for Scientific Research (to G.-J.B.) and ERC-ADG grant 101020769 of the European Commission (to G.-J.B.). R.H. was funded by the GBS/CIDP Foundation International and the T2B collaboration project funded by PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF.
| Funders | Funder number |
|---|---|
| Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) | 718.015.003 |
| TOP-PUNT | |
| Netherlands Organization for Scientific Research | 101020769 |
| ERC-AdG | LSHM18055-SGF |
| European Commission - GBS/CIDP Foundation International | |
| European Research Council (ERC) | 101020769 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Chemoenzymatic synthesis of human natural killer-1-containing glycans and application as serum antibodies probes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver